Shots: Dragonfly to receive $475M as up front and is eligible to receive development, regulatory and commercial milestones in addition to 24% royalties on global sales of the therapy. BMS to get exclusive WW license to Dragonfly’s IL-12 investigational immunotherapy program, including its extended half-life cytokine DF6002 BMS will be responsible for the development & […]Read More
Shots: Sangamo to receive $75M upfront within 30 days, $720M milestone payments including up to $420M in development milestones and up to $300M in commercial milestones plus royalties on sales of the product. Additionally, Sangamo to take care of certain research and manufacturing activities funded by Novartis Novartis to get exclusive license rights of ZFP-TFs […]Read More
Shots: Hansa to receive $10M up front, up to $397.5M as development, regulatory & commercial milestones. Hansa will book all sales of therapy and will get royalties on gene therapy sales that arises from treating Ab-positive patients enabled through imlifidase pre-treatment Sarepta get an exclusive WW license to develop and promote imlifidase as a pre-treatment […]Read More
Shots: Alpine to receive $60M up front, ~$805M as option exercise fee, development, regulatory and commercial milestones along with royalties on net sales of ALPN-101 AbbVie to get an option to exclusively license ALPN-101, following exercising the option, AbbVie will conduct all future clinical development, manufacturing, and commercialization activities for ALPN-101 During the option period, […]Read More
Shots: Accent to receive $55M upfront and $1.1B as co-development option and milestone payment, plus royalties and profit split based on the option to co-develop and co-commercialize RMP-targeting therapies for the treatment of cancer in the US Accent will be responsible for research and development activities for a nominated preclinical program through to the end […]Read More
Shots: AbbVie to get an exclusive global license to develop and commercialize JAB-3068 and JAB-3312 from Jacobio AbbVie will provide undisclosed R&D cost to Jacobio for conducting early global CTs of JAB-3068 and JAB-3312. In addition, Jacobio has an exclusive option before registration trial initiation to develop and commercialize the SHP2 program in mainland China, […]Read More
Shots: Vividion to receive $135M upfront in cash and is eligible to receive billion dollars preclinical, development and commercial milestones along with royalties on sales of commercialized products resulting from the collaboration Vividion will be responsible for early drug discovery and pre-clinical development for selected programs and has the right to conduct clinical development up […]Read More
Shots: Recursion to get exclusive WW rights to develop and commercialize TAK-733 for the treatment of a hereditary cancer syndrome and related areas of oncology Recursion will utilize its automated drug discovery platform to discover the potential of TAK-733 by testing 200+ potential molecules from Takeda’s library against cancers carrying mutations TAK-733 is identified as […]Read More
Shots: :stohththShots: The companies intend to establish manufacturing suites at Lonza’s facilities in the US and Switzerland to manufacture mRNA-1273 at both sites. The collaboration will deploy Lonza’s global expertise in technology transfer and manufacturing while the technology transfer expected to begin in Jun’2020 The focus of the collaboration is to enable the manufacturing of […]Read More
Shots: The collaboration will bring Oxford’s recombinant adenovirus vaccine, ChAdOx1 nCoV-19 to the patients and will enable AstraZeneca to be responsible for the development and WW manufacturing and distribution of the vaccine The alliance will combine Oxford’s expertise in vaccinology and AstraZeneca’s global development, manufacturing and distribution capabilities to combat the pandemic ChAdOx1 is based […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
